Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.

Authors
Zhang-Y; Martin-SW; Rose-CE Jr.; Biagini-RE; Franzke-LH; Smith-JP; Sammons-DL; Robertson-SA; McNeil-MM
Source
Pharmacoepidemiol Drug Saf 2008 Nov; 17(11):1060-1067
NIOSHTIC No.
20034697
Abstract
Background: in 2002, CDC initiated the Anthrax Vaccination Program (AVP) to provide voluntary pre-exposure anthrax vaccination for individuals at high risk for exposure to Bacillus anthracis spores. The AVP offered an opportunity to investigate hypothesized reasons for a reported gender difference in injection site adverse events (AEs) following anthrax vaccine adsorbed (AVA). Objectives: to evaluate in women the impact of body mass index (BMI), pre-vaccination serum progesterone levels, and pre-vaccination anti-anthrax protective antigen immunoglobulin G concentrations (anti-PA IgG) on the occurrence of AEs following subcutaneous AVA vaccination. Methods: participants' BMI was determined at enrollment. Also, pre-vaccination blood samples were assayed for serum progesterone and anti-PA IgG. Post-vaccination solicited AEs were recorded by participants using a 4-day diary card. Results: obese group had an elevated risk for arm soreness. Decreased pre-vaccination serum progesterone level was associated with arm swelling. Increased pre-vaccination anti-PA IgG was associated with itching on the arm; and within the obese group, was associated with arm swelling, lump or knot, redness, soreness, and warmth. Conclusions In AVA vaccinated women, obesity was associated with arm soreness and decreased pre-vaccination serum progesterone levels were associated with increased rate of arm swelling. Increased pre-vaccination anti-PA IgG may be associated with an increased frequency of itching on the arm, and in obese women, may increase the occurrence of arm swelling, lump or knot, redness, and warmth. Administering AVA according to a woman's menstrual phase may reduce the occurrence of certain injection site reactions.
Keywords
Vaccines; Immune-reaction; Immune-system; Immunological-tests; Biological-effects; Biological-factors; Body-weight; Women
Contact
Michael M. McNeil, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS C-25, Atlanta, GA 30333
CODEN
PDSAEA
Publication Date
20081101
Document Type
Journal Article
Email Address
mmm2@cdc.gov
Fiscal Year
2009
NTIS Accession No.
NTIS Price
Issue of Publication
11
ISSN
1053-8569
NIOSH Division
DART
Priority Area
Healthcare and Social Assistance; Manufacturing
Source Name
Pharmacoepidemiology and Drug Safety
State
OH; GA
TOP